Press release
August 10, 2026
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed Inc. (CRVO)
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented